ClinicalTrials.gg
RecruitingNCT05774483SECOND N0Updated Jul 17, 2025

Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative

An interventional study of Sentinel Node Biopsy and Limited Elective Neck Dissection in Mouth Neoplasms, Oral Cancers and Oral Squamous Cell Carcinoma (OSCC), sponsored by Tata Memorial Hospital. Recruiting at 3 sites in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Tata Memorial Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
508
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Mouth Neoplasms with a site in India — 8 open to participants now, 9 under way, 1 of them phase 3. Mouth Neoplasms · India.

Planned enrollment
6th of 22
508 · median 140
Started
2025
with 2 others
No phase
12 of 23
5 open now
Registered
14th of 23
by date
Lead sponsor
8 of 23
Tata Memorial Hospital

Among the 23 studies in Mouth Neoplasms with a site in India, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 12 with no phase, and was the 14th registered.

Mouth Neoplasms

447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.

Browse Mouth Neoplasms studies →

Open to participants now

8 of the 23 studies in Mouth Neoplasms with a site in India are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Mouth Neoplasms with a site in India, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the survival outcomes, morbidity and cost-effectiveness of sentinel node biopsy versus limited elective neck dissection in node-negative early oral cancers.

The main questions it aims to answer are:

  • Survival outcomes
  • Morbidity outcomes
  • Cost-effectiveness

Participants will either undergo sentinel node biopsy followed by completion neck dissection if sentinel node is reported to be metastatic (SNB) or limited elective neck dissection where level IIb will be cleared only if level IIa is metastatic (limited END). The study will compare the outcomes in the two cohorts.

Read the detailed description

Based on the current literature, we know that elective neck dissection (END) is mandatory in clinically node-negative early oral cancers. However, this leads to overtreatment and morbidity in about 55-80% of patients. The emergence of recent level I evidence makes SNB the standard of care in this setting. However, its limitation of being a two-staged procedure, steep learning curve, the burden on resources, lack of infrastructure, short-lasting decrease in morbidity and lack of cost-effectiveness data limits its wide applicability. It is our routine departmental practice of performing limited neck dissection clearing level I-III/IV sparing level IIb which is cleared only if level IIa is metastatic. It is hypothesized that limited END would limit the morbidity of shoulder dysfunction and be a more feasible and cost-effective treatment option which could be a suitable alternative to SNB in this setting without compromising the survival outcomes. With this background, we propose to embark upon a phase III RCT comparing the oncologic outcomes and morbidity of SNB versus limited END. We hypothesize that limited END would have survival outcomes non-inferior, morbidity similar to SNB with higher cost-effectiveness.

Aims and objectives:

Aim To compare the survival outcomes, morbidity and cost-effectiveness of SNB versus limited END in node-negative early oral cancers

Primary objective

1) Overall survival

Secondary objectives

  1. Shoulder morbidity (key secondary endpoint) longitudinally up to 2 years
  2. Disease-free survival
  3. Neck nodal recurrence-free survival
  4. Other side effects (chyle leak, hematoma, lymphoedema)
  5. Longitudinal Quality of life up to 2 years
  6. Cost-effective analysis

Exploratory objectives Blood and tumour tissue will be collected and banked for biomarker studies. Exploratory analyses will be conducted at a later date. Efforts may be directed to identify the biomarkers to predict nodal metastasis.

03

Conditions studied

  • Mouth Neoplasms
  • Oral Cancers
  • Oral Squamous Cell Carcinoma (OSCC)
  • Oral Squamous Cell Carcinomas
  • Sentinel Lymph Node Biopsy
  • Sentinel Lymph Node Biopsy (SLNB)
  • Sentinel Lymph Node

Keywords

  • mouth neoplasms
  • neck dissection
  • sentinel lymph node biopsy
  • survival
  • morbidity
  • oral cancers
  • oral squamous cell carcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years of age
  2. -proven invasive squamous cell carcinoma involving the site tongue and buccal mucosa
  3. T1 and T2 lesions as per AJCC TNM 8 edition
  4. Clinicoradiologically node negative
  5. Amenable to per oral excision
  6. Treatment naïve
  7. No other site of

Exclusion criteria

Exclusion Criteria:

  1. Previous surgery in the head and neck region,
  2. Upper alveolar or palatal lesions
  3. Large heterogeneous leukoplakia or other premalignant lesions
  4. Previous in the head and neck region
  5. Patients requiring the free flap reconstruction
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
508 participants (estimated)

Study arms

  • Active comparator
    Sentinel node biopsy

    Procedure: Sentinel Node Biopsy

  • Experimental
    Limited elective neck dissection

    Procedure: Limited Elective Neck Dissection

Interventions

  • ProcedureSentinel Node Biopsy

    The Sentinel node will be localized after injecting peritumoral nano colloid followed by dynamic lymphoscintigraphy and SPECT localization. Methylene blue or indocyanine green may be used but not mandatory as an adjunct for lymphoscintigraphy for node localization. Intraoperatively the node will be identified using a hand-held gamma probe. The sentinel node will be processed on a frozen section, histopathological processing with serial step sectioning, and immunohistochemistry. If reported as metastatic, then a single-stage or second-stage completion neck dissection will be performed.

  • ProcedureLimited Elective Neck Dissection

    Patients who are allocated to the limited END arm will undergo dissection of level I, IIa and III/IV nodes sparing level IIb. Level IIa will be subjected to a frozen section and if reported as metastatic will mandate clearance of level IIb.

06

What researchers measure

Primary outcomes

  1. Overall survival

    Defined from the date of randomization to death due to any cause

    Time frame: 3 years

Secondary outcomes

  1. Shoulder morbidity

    It will be assessed using the neck dissection impairment index (NDII). The range of movement of the shoulder will also be assessed using a goniometer

    Time frame: Longitudinally at preoperatively, 3 months, at 6 months, 12 months and 24 months of treatment

  2. Neck nodal recurrence

    Defined from the date of randomization to isolated neck node recurrence or death due to any cause

    Time frame: 3 years

  3. Disease free survival

    Defined from the date of randomization to any recurrence (local, regional or distant metastasis) and second primary in the oral cavity

    Time frame: 3 years

  4. Health related Quality of life

    Quality of life will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) QLQ C30 and QLQ HN35 instruments

    Time frame: Longitudinally at preoperatively, 3 months, at 6 months, 12 months and 24 months of treatment

  5. Adverse events related to the surgical procedure and lymphedema

    Details of the intra and perioperative delay including injury to critical structures, chyle leak, haemorrhage, and head and neck lymphedema

    Time frame: The lymphedema rating will be done at 3 months, at 6 months, 12 months and 24 months of treatment

  6. Cost effectiveness

    Based on direct cost comparison

    Time frame: 3 years

07

Study locations

1 of 3 sites recruiting
  • Tata Memorial Hospital
    Mumbai, Maharashtra 400012, India
    Recruiting
  • ACTREC
    Navi Mumbai, Maharashtra, India
    Not yet recruiting
  • Mpmmcc & Hbch
    Varanasi, Uttar Pradesh, India
    Not yet recruiting
08

References and documents

Publications

  • Garrel R, Poissonnet G, Moya Plana A, Fakhry N, Dolivet G, Lallemant B, Sarini J, Vergez S, Guelfucci B, Choussy O, Bastit V, Richard F, Costes V, Landais P, Perriard F, Daures JP, de Verbizier D, Favier V, de Boutray M. Equivalence Randomized Trial to Compare Treatment on the Basis of Sentinel Node Biopsy Versus Neck Node Dissection in Operable T1-T2N0 Oral and Oropharyngeal Cancer. J Clin Oncol. 2020 Dec 1;38(34):4010-4018. doi: 10.1200/JCO.20.01661. Epub 2020 Oct 14. PubMed 33052754 ↗
  • D'Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, Agarwal JP, Pantvaidya G, Chaukar D, Deshmukh A, Kane S, Arya S, Ghosh-Laskar S, Chaturvedi P, Pai P, Nair S, Nair D, Badwe R; Head and Neck Disease Management Group. Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer. N Engl J Med. 2015 Aug 6;373(6):521-9. doi: 10.1056/NEJMoa1506007. Epub 2015 May 31. PubMed 26027881 ↗
  • Hutchison IL, Ridout F, Cheung SMY, Shah N, Hardee P, Surwald C, Thiruchelvam J, Cheng L, Mellor TK, Brennan PA, Baldwin AJ, Shaw RJ, Halfpenny W, Danford M, Whitley S, Smith G, Bailey MW, Woodwards B, Patel M, McManners J, Chan CH, Burns A, Praveen P, Camilleri AC, Avery C, Putnam G, Jones K, Webster K, Smith WP, Edge C, McVicar I, Grew N, Hislop S, Kalavrezos N, Martin IC, Hackshaw A. Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort. Br J Cancer. 2019 Nov;121(10):827-836. doi: 10.1038/s41416-019-0587-2. Epub 2019 Oct 15. PubMed 31611612 ↗
  • Dhar H, Vaish R, D'Cruz AK. Comment on "Nationwide randomised trial evaluating elective neck dissection for early-stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort.". Br J Cancer. 2020 Sep;123(7):1198-1199. doi: 10.1038/s41416-020-0981-9. Epub 2020 Jul 16. No abstract available. PubMed 32669674 ↗
  • Vaish R, Hawaldar R, Gupta S, Dandekar M, Shah S, Chaukar D, Pantvaidya G, Deshmukh A, Chaturvedi P, Pai P, Nair D, Nair S, Thakur M, Ghosh-Laskar S, Agarwal JP, D'Cruz AK. N0 neck trial: Does intensification of follow-up (Ultrasound + Physical Examination) influence outcomes in early-stage oral cancer? Eur J Cancer. 2024 Jun;204:114064. doi: 10.1016/j.ejca.2024.114064. Epub 2024 Apr 16. PubMed 38705028 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2032, 84 months after the start.

Of 98 non-industry interventional studies with no phase under Mouth Neoplasms, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 97. This study's planned 84 months is above that.

Counting every sponsor, half of 99 studies reached it within 30 months; a quarter within 17 and three quarters within 107.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
Mar 17, 2023
StartActual
Apr 16, 2025
Primary completionEst.
Apr 2032
CompletionEst.
Apr 2034
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05774483
Lead sponsor
Tata Memorial Hospital
Collaborators
Tata Memorial Centre
Responsible party
Richa Vaish (Professor and Surgeon, Tata Memorial Hospital) — Principal investigator
First posted
Mar 17, 2023
Start date
Apr 16, 2025
Primary completion
Apr 2032 (estimated)
Completion
Apr 2034 (estimated)
Last update
Jul 17, 2025

Study contacts

Richa Vaish, MS, M.Ch
Contact
drvaishricha@gmail.com
02224177000 ext. 7238
Richa Vaish, MS, M.Ch
principal investigator · Tata Memorial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion